Background: The function of serum immunoglobulin D (IgD) is still undetermined. It is speculated that it might play a role in autoimmune and infectious diseases. Therefore we tested sera from patients suffering from those diseases for AEIDA directed against autologous oral mucosal epithelial cells (AOMEC). Patients and Methods: Patients suffering from Crohns disease (n=19), ulcerative colitis (n=11), rheumarthritis (n=36), systemic lupus erythematodes (n=9), glomerulonephritis (n=7), viral hepatitis B and C (n=24), bacterial infections (n=21) and for a comparison healthy volunteers (n=71) were tested for AEIDA. Swabs from the patients and volunteers oral cavity containing lots of AOMEC were incubated with either autologous sera or the patients sera respectively. After washing, cells were incubated with a rabbit anti-human IgD antibody. Thereafter cells were washed again and incubated with a fluoresceinated goat anti-rabbit Ig antibody. Fluorescent cells were counted under a Zeiss microscope. Results: Rates of fluorescent cells were significantly increased in patients with Crohns disease (15 ± 2.5%), ulcerative colitis (5 ± 1,2 %), rheumarthritis (4.8 ± 1.3%), systemic lupus erythematodes (12 ± 2.9%), viral hepatitis B and C (9,5 ± 1,7 %) and bacterial infections (6,1 ± 2,1 %) as compared to healthy volunteers (1,7 ± 1,2 %). Incubation of the volunteers oral mucosal epithelial cells (OMEC) with positive patients sera resulted in a bright fluorescence of those cells. No correlation was detected between fluorescence rates and independent inflammation parameters i.e. CRP, leucocytes or Crohns activity index. Conclusion: AEIDA against AOMEC and volunteers OMEC are found in the sera of patients suffering from autoimmune, viral and bacterial diseases. The pathogenicity of those antibodies in the course of the diseases is not yet clear.
«
Background: The function of serum immunoglobulin D (IgD) is still undetermined. It is speculated that it might play a role in autoimmune and infectious diseases. Therefore we tested sera from patients suffering from those diseases for AEIDA directed against autologous oral mucosal epithelial cells (AOMEC). Patients and Methods: Patients suffering from Crohns disease (n=19), ulcerative colitis (n=11), rheumarthritis (n=36), systemic lupus erythematodes (n=9), glomerulonephritis (n=7), viral hepat...
»